<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Arsenic exposure and chronic poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Arsenic exposure and chronic poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Arsenic exposure and chronic poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rose H Goldman, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Arsenic toxicity can vary greatly depending on the chronicity and dose of exposure and the chemical properties of the arsenical compound (eg, valence, complexed structures). Arsenic exposure can be asymptomatic or cause skin changes, hepatotoxicity, cardiovascular effects (eg, dysrhythmias), sensorimotor neuropathy, and diabetes mellitus. Latent or long-term effects of arsenic exposure include an increased risk of cancers, even after exposure has ceased. Clinicians may encounter questions regarding arsenic in various clinical circumstances, such as the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A patient with rash, other abnormalities, or no signs or symptoms who has ongoing chronic arsenic exposure from drinking water that is highly contaminated with arsenic or has mild arsenic elevations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A patient with non-diagnosed and non-specific symptoms (eg, neurologic) and someone questions arsenic toxicity or tests the urine (or blood) for heavy metals and the total arsenic concentration is above the reference range </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A potential occupational exposure </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When using <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> to treat a patient with promyelocytic leukemia </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A critically ill patient with symptoms of acute inorganic arsenic or arsine gas poisoning (very rare) </p><p></p><p>This topic focuses on the evaluation and management of patients with chronic arsenic exposure, chronic poisoning, and latent effects. </p><p>The evaluation and treatment of the acutely poisoned patient are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="headingAnchor" id="H2237656463"><span class="h1">PATHOPHYSIOLOGY OF ARSENIC TOXICITY</span></p><p class="headingAnchor" id="H2179538862"><span class="h2">Chemistry</span><span class="headingEndMark"> — </span>The toxicity of an arsenical compound depends on arsenic's valence and complexed chemical structures. Arsenic is classified as a metalloid because it complexes with metals, but also reacts with other elements such as oxygen, hydrogen, chlorine, carbon, and sulfur. Arsenicals can be grouped according to their valence states: elemental (0), trivalent (+3), pentavalent (+5), and arsine gas (-3). They can further be grouped as inorganic and organic. In general, trivalent arsenicals are more toxic than pentavalent, and inorganic arsenicals are more toxic than organic.</p><p>Elemental arsenic is rare; arsenic exists more commonly as organic or inorganic compounds [<a href="#rid1">1-3</a>]. Inorganic arsenic exists in trivalent (arsenite; As<sup>3+</sup>) or pentavalent (arsenate; As<sup>5+</sup>) forms. Organic forms are methylated metabolites (eg, monomethylarsonic acid, dimethylarsinic acid) of inorganic forms. <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">Melarsoprol</a> is a highly-toxic trivalent organic arsenical that has been used to treat late-stage trypanosomiasis [<a href="#rid4">4</a>]. There are also organic arsenicals found in foods that are considered to have little or no toxicity, such as arsenobetaine (found in fish and crustaceans and known as "fish arsenic") and arsenosugars (found in seaweed and marine algae) [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2919975906"><span class="h2">Toxicokinetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption</strong> – Arsenical compounds are well absorbed after ingestion or inhalation. The gastrointestinal absorption of most water soluble trivalent and pentavalent arsenicals exceeds 90 percent, whereas poorly soluble compounds such as <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> are less well absorbed [<a href="#rid1">1</a>]. Peak serum arsenic concentrations are reached approximately 30 to 60 minutes after a single oral dose.</p><p></p><p class="bulletIndent1">Low-level skin absorption from chronic application of arsenical products is possible, but absorption from single use is negligible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – Arsenic readily enters red blood cells and then quickly distributes, initially to the liver, kidneys, muscle and skin, and ultimately to all tissues including the brain [<a href="#rid1">1</a>]. Studies of humans receiving intravenous arsenic radioisotopes describe clearance from blood in three phases [<a href="#rid1">1,6,7</a>]: initially very rapid (two to three hours) in which more than 90 percent is cleared through redistribution and renal excretion, then gradually over three hours to seven days, followed by a slower clearance of ten days or more. The rapid clearance in the first two phases explains why blood testing is less reliable than urine testing for assessing chronic exposure; blood testing can be helpful very early after exposure in cases of acute poisoning. Arsenic is handled similar to phosphate and incorporates into tissue in place of phosphate.</p><p></p><p class="bulletIndent1">Chronic ingestion of small amounts of inorganic arsenic results in the highest concentration in hair, nails, skin, and tissues rich in cysteine-containing proteins [<a href="#rid1">1,8</a>]. Arsenic can also cross the placenta and accumulate in the fetus [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism</strong> – The majority of trivalent arsenicals are metabolized via methylation, which decreases toxicity and increases elimination. For example, <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> is methylated to form monomethylarsonic acid (MMA) followed by dimethylarsinic acid (DMA) and excreted predominantly in the urine [<a href="#rid1">1,9-11</a>]. Pentavalent arsenicals and arsine gas are converted to trivalent arsenicals in vivo. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elimination</strong> – Unchanged arsenic, methylated metabolites, and arsenobetaine are eliminated in the urine. In volunteers, half of a measurable oral dose is excreted within the first 28 hours, and the rest tapered off over the next three days [<a href="#rid10">10</a>]. </p><p></p><p class="headingAnchor" id="H1842818064"><span class="h2">Mechanism of toxicity</span><span class="headingEndMark"> — </span>Primary target organs for arsenic toxicity are the gastrointestinal tract, skin, bone marrow, kidneys, and peripheral nervous system. </p><p>Trivalent arsenicals, both inorganic and organic, are considered the most toxic. These avidly bind to sulfhydryl groups on proteins, glutathione, and cysteine and interfere with numerous enzyme systems, such as those involved in cellular respiration (inhibiting pyruvate dehydrogenase), gluconeogenesis and glucose uptake, and glutathione metabolism [<a href="#rid1">1</a>]. Pentavalent arsenicals and arsine gas may also directly uncouple oxidative phosphorylation.</p><p>Molecular mechanisms of latent disease (such as increased risk of cancer, disturbances of immune function) associated with early-life arsenic exposure are being investigated [<a href="#rid12">12</a>]. One likely mechanism is "epigenetic reprogramming," or changes to gene expression (eg, DNA methylation) that ultimately lead to future increased susceptibility to developing cancer.</p><p>Studies have described the effect of arsenic on vascular endothelial cells and proposed mechanisms for induced atherosclerosis, such as increased platelet aggregation, reduced fibrinolysis, and upregulation of expression of tumor necrosis factor-alpha, interleukin-1, vascular cell adhesion molecule, and vascular endothelial growth factor [<a href="#rid13">13</a>]. </p><p>Elemental arsenic and some organic forms of arsenic such as arsenobetaine are likely non-toxic. Other organic forms, such as arsenocholine and arsenosugars, undergo minor metabolism to DMA and have uncertain toxicity, but likely negligible toxicity with routine dietary intake [<a href="#rid1">1-3,5,10,14,15</a>].</p><p class="headingAnchor" id="H1229512021"><span class="h1">SOURCES OF EXPOSURE AND REGULATORY LIMITS</span></p><p class="headingAnchor" id="H14059280"><span class="h2">Drinking water</span><span class="headingEndMark"> — </span>Exposures can occur from arsenic leaching into drinking water from natural sources (eg, volcanic eruptions, soil, rock) and from mining activities. Arsenic exposure from drinking water occurs in many parts of the world and causes a wide range of health effects [<a href="#rid2">2,5,16-21</a>]. Soluble arsenic dissolved in water is tasteless and odorless. In some locations, water contamination presents an enormous health hazard, such as in the poisoning epidemic in West Bengal, India, and Bangladesh. More than one million people have been drinking water from newly drilled wells that were contaminated with large amounts of arsenic (concentrations &gt;50 mcg/L) that leached from natural underground sources [<a href="#rid2">2,22-26</a>]. Thousands of people have developed arsenic-related skin lesions, liver problems, decreased motor function, and neuropathy [<a href="#rid27">27</a>].</p><p>Although less common, there are case reports of arsenic poisoning in the United States (US) due to contaminated well water, and in rural Australia, from stream water thought to be contaminated from a nearby mine [<a href="#rid28">28,29</a>]. In the US, water intended for drinking generally contains an average of 2 mcg/L (2 parts per billion [ppb]) of arsenic, although approximately ten percent of surface water sources in the North Central region of the US have concentrations exceeding 20 mcg/L (20 ppb) [<a href="#rid14">14,30</a>]. The US Geological Survey (USGS) maintains a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.usgs.gov%2Fmission-areas%2Fwater-resources%2Fscience%2Farsenic-and-drinking-water&amp;token=xfqs4AdbTwt41vHomrScYcJ50OS2Jx1V9DpUCbIrtZbMLfd60vTfktuu5jXZY4cocKEC4%2BpvNESZcIFhcXv9sR%2FoRYsmlCOkgDAYE8WAJLE%3D&amp;TOPIC_ID=2778" target="_blank">website</a> describing arsenic concentrations in water sources. In the US, private well water is not regulated and can have elevated arsenic concentrations [<a href="#rid31">31</a>].</p><p>The US and other countries have focused on lowering drinking water arsenic concentration limits to prevent long-term adverse health outcomes (eg, cancer, bronchiectasis) to well below concentrations expected to cause subacute clinical manifestations. The World Health Organization (WHO), US Environmental Protection Agency (EPA), and the US Food and Drug Administration (FDA) (which regulates bottled water) have set a regulatory limit of 10 mcg/L (10 ppb) of arsenic in drinking water [<a href="#rid2">2,21,32-34</a>].</p><p>Some experts argue for even lower thresholds to reduce carcinogenic risks [<a href="#rid35">35</a>]. Even at a concentration of 10 ppb, estimates of excess lifetime cancer risk in a 70 kg person drinking one liter of water per day are 12 and 23 per 10,000 individuals for bladder cancer (women and men, respectively) and 18 and 24 per 10,000 individuals for lung cancer (women and men, respectively) [<a href="#rid35">35</a>]. Some experts feel this excess cancer risk is too high and advocate for lower maximum contaminant levels (MCL). For example, the state of New Jersey has set an arsenic MCL of 5 mcg/L.</p><p class="headingAnchor" id="H2037308291"><span class="h2">Dietary ingestion</span><span class="headingEndMark"> — </span>Varying amounts of inorganic arsenic are consumed from food, liquids, and dietary supplements [<a href="#rid36">36,37</a>]. Inorganic arsenic in food typically originates from contaminated water or soil [<a href="#rid38">38-40</a>]. A US individual's dietary intake of inorganic arsenic has been estimated to range from 1 to 20 mcg per day [<a href="#rid14">14,15</a>].<strong> </strong>Examples of dietary sources of arsenic include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Juice </strong>– There have been concerns about arsenic contamination in some apple and grape juices [<a href="#rid41">41</a>]. The FDA performed testing from 2005 to 2011 of 160 apple juice samples from several countries, noting mild elevation of the toxic arsenic species in some samples [<a href="#rid34">34,42</a>]. The source of the arsenic contamination is unclear but may be from arsenic-containing pesticides residues (banned in the US, but still used in other countries) or contaminated water used in processing. The FDA has not set a reference range for juices, but has proposed an "action level" of 10 ppb for inorganic arsenic in apple juice (similar to bottled water) [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rice products</strong> – Arsenic contamination has been found in rice products [<a href="#rid37">37-39,44,45</a>], which has raised particular concerns since rice cereal is often one of the first foods given to children and rice is a staple food in many parts of the world. In a 2012 study, a toddler milk formula containing organic brown rice syrup as a sweetener had total arsenic concentrations of up to six times the EPA safe drinking water limit [<a href="#rid38">38</a>]. Concerns regarding arsenic exposure have led to updated recommendations for how to reduce arsenic exposure in an infant's diet [<a href="#rid46">46</a>]. In 2016,the FDA proposed a limit or "action level" of 100 ppb of inorganic arsenic for infant rice cereal, which parallels guidance from the European Commission for rice foods for infants and young children [<a href="#rid47">47</a>]. These interventions to reduce early-life arsenic exposure since children may be more susceptible to the latent effect [<a href="#rid12">12,47</a>]. (See <a class="local">'Pediatrics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chicken</strong> – There is evidence that inorganic arsenic may accumulate in the meat of chickens treated with a growth-promoting arsenical drug (roxarsone) and arsenical compounds used to control intestinal parasites [<a href="#rid48">48-50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complementary and alternative medicines</strong> – Ayurvedic remedies, homeopathic remedies, and herbal preparations have occasionally been contaminated with arsenic [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohols </strong>–Illicitly distilled alcohol products (ie, "moonshine") occasionally contain arsenic [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fish, shellfish, or seaweed</strong> – These typically contain organic forms of arsenic, such as arsenobetaine ("fish arsenic"), which are felt to be relatively non-toxic [<a href="#rid5">5</a>]. However, their presence can complicate interpretation of urine testing results. (See <a class="local">'Urine'</a> below.)</p><p></p><p class="bulletIndent1">Hijiki (hiziki) seaweed has occasionally been found to contain high levels of inorganic arsenic [<a href="#rid54">54,55</a>].</p><p></p><p class="headingAnchor" id="H2707055430"><span class="h2">Occupational</span><span class="headingEndMark"> — </span>Arsenic is no longer produced in the US, but is still imported [<a href="#rid14">14</a>]. In order to minimize occupational exposure, the US Occupational Safety and Health Administration (OSHA) has set a workplace air permissible exposure limit (PEL) of 10 mcg/m<sup>3</sup> as a time-weighted average over an eight-hour work day [<a href="#rid56">56</a>]. The National Institute of Occupational Safety and Health (NIOSH) is more conservative and has advised a recommended exposure limit (REL) of 2 mcg/m<sup>3</sup> (over a 15-minute exposure) [<a href="#rid57">57</a>]. Human-made exposures derive from various sources including the following [<a href="#rid1">1,3,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pesticides</strong> – Arsenic exposure can result from use and manufacture of arsenic-containing pesticides (eg, sodium arsenate ant killer, "Terro"). Although regulations banned their use in the US starting in 1991, some products are still used in other countries and/or found in older stored supplies (eg, <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a>, sodium arsenite, calcium arsenite, arsenic acid), ant poisons, and herbicides (eg, cacodylic acid) [<a href="#rid58">58</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smelting and refining</strong> – Individuals working in smelting and refining are at risk of inhaling dust containing arsenic. For example, copper smelters would be expected to have urinary arsenic concentrations of 30 to 35 mcg As/g creatinine from exposure to air with arsenic concentrations averaging 10 mcg/m<sup>3</sup> [<a href="#rid9">9</a>]. (See <a class="local">'Urine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other industries</strong> – Other industries where workers can be exposed to arsenic include decorative glass-making, metallurgy, semiconductor manufacturing (exposed to gallium arsenide), and mining [<a href="#rid59">59</a>]. </p><p></p><p class="headingAnchor" id="H4232243703"><span class="h2">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Soil</strong> – Arsenic is a naturally occurring element found in the earth's crust and within numerous ores. Human exposures can occur from leaching from soil and rocks from natural sources, such as volcanic eruptions, and from occupational sources, such as hazardous waste or superfund sites [<a href="#rid2">2,3,14,15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pressure-treated wood</strong> – There are reports of arsenic poisoning from inhalation and skin contact of dust in people sawing pressure-treated wood and from inhalation of arsenic-contaminated smoke from burning pressure-treated wood in fireplaces or campfires [<a href="#rid14">14</a>]. In order to protect lumber from insect infestation, decay, and marine environments, pressure-treated wood undergoes infusion of preservatives, which can include chromated arsenicals such as chromium copper arsenate (CCA) or ammoniacal copper zinc arsenate (ACZA). In 2003, US manufacturers began a voluntary phase-out of arsenic-containing wood preservatives for residential applications such as play structures, picnic tables, decks, and fencing [<a href="#rid14">14,60</a>]. However, there are still existing wood structures that have CCA-treated elements [<a href="#rid61">61</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutics </strong>– Arsenicals have been previously used therapeutically to treat syphilis (arsphenamine) and skin conditions (Fowler's solution) and presently used to treat late-stage trypanosomiasis (<a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">melarsoprol</a>) and acute promyelocytic leukemia (<a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a>) [<a href="#rid3">3,62-64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fossil fuel combustion</strong> – Human exposure can occur during burning of arsenic containing fossil fuel (eg, coal), such as from coal-powered power plants or incinerators [<a href="#rid3">3</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pica </strong>– Chronic arsenic toxicity has been described from consumption of broken clay terracotta pots [<a href="#rid65">65</a>]. </p><p></p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL FEATURES AND LATENT EFFECTS OF CHRONIC EXPOSURE</span></p><p class="headingAnchor" id="H451292385"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Clinical features of "chronic" toxicity develop over months to years and can occur after low to moderate-level, prolonged exposure to arsenic or as a sequela of acute, large-dose poisoning. Chronic toxicity from the former can have an insidious onset and thus be difficult to recognize and diagnose. Any of the toxicities described below can occur. </p><p>Latent effects from exposure refers to the malignancies, skin changes, cardiac effects, and neurobehavioral changes (which may be seen in children) that can develop years to decades after an acute or chronic exposure, even if the exposure has ceased. Chronic exposure increases future risk of cancer more than acute poisoning [<a href="#rid16">16</a>].</p><p>The clinical features of chronic toxicity are different than those that occur with acute toxicity, which is typically from a single ingestion of a large dose of arsenic. Acute toxicity starts with gastrointestinal symptoms followed by cardiovascular collapse if sufficiently high dose. Following survival from an acute poisoning, subacute signs and symptoms (eg, neuropathy and skin lesions) can develop over one to three weeks followed by features of chronic toxicity. </p><p class="headingAnchor" id="H2451498960"><span class="h2">All-cause and cardiovascular mortality</span><span class="headingEndMark"> — </span>Chronic exposure to arsenic has been associated with increased all-cause and cardiovascular mortality. The Health Effects of Arsenic Exposure Longitudinal Study (HEALS) followed 11,746 patients in Bangladesh for almost seven years and found that chronic arsenic exposure through drinking water (&gt;150 mcg/L) was associated with increased all-cause mortality (hazard ratio [HR] 1.68, 95% CI 1.26-2.23) and increased cardiovascular mortality (HR 1.92, 95% 1.07-3.43) [<a href="#rid25">25,66</a>]. Persons drinking well water with arsenic concentrations &gt;12 mcg/L also had an increase in mortality rate for cardiovascular disease (271 versus 214 per 100,000 person years) [<a href="#rid66">66</a>]. There was a dose-response relationship between increasing arsenic concentrations in well water and cardiovascular deaths, as well as a synergistic effect with tobacco smoking. Additionally, decreasing exposure did not reduce an individual's mortality risk, thus regulatory agencies have set limits and created strategies to prevent primary exposure to inorganic arsenic from both naturally occurring and man-made sources [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4186605058"><span class="h2">Cancer</span><span class="headingEndMark"> — </span>Inorganic arsenic is a recognized carcinogen. The International Agency for Research on Cancer (IARC) has classified inorganic arsenic as carcinogenic to humans (Group 1) and arsenic metabolites dimethylarsinic acid and monomethylarsonic acid as possibly carcinogenic to humans (Group 2B) [<a href="#rid67">67</a>]. Their comprehensive review found sufficient evidence that inorganic arsenic exposure increases risk of lung, bladder, and skin cancers and found a positive association for kidney, liver, and prostate cancer. Epidemiologic studies subsequent to the IARC report have found similar results [<a href="#rid68">68-71</a>]. Thus, regulatory actions limit arsenic exposure in both environmental and occupational settings. (See <a class="local">'Sources of exposure and regulatory limits'</a> above.)</p><p>Evidence for various malignancies (although not exhaustive) includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung cancer</strong> – Inorganic arsenic exposure increases the risk of developing lung cancer [<a href="#rid67">67,68,70,72</a>]. Observational studies from Chile found a dose-response relationship between arsenic drinking water concentration and lung cancer [<a href="#rid72">72,73</a>]. The risk for lung cancer starts to increase when arsenic water concentrations reach approximately 60 mcg/L, with an adjusted relative risk of almost nine with concentrations of 200 to 400 mcg/L. Mortality rates from lung cancer can decline following the elimination of arsenic from drinking water [<a href="#rid74">74</a>]. There is also evidence that arsenic and tobacco smoking may synergetically increase the risk of lung cancer [<a href="#rid73">73,75</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer", section on 'Occupational and environmental carcinogens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bladder cancer</strong> – Inorganic arsenic exposure increases the risk of developing bladder cancer [<a href="#rid67">67,68</a>]. A cohort study in Taiwan demonstrated a dose-response relationship between arsenic exposure in drinking water and bladder cancer [<a href="#rid76">76</a>]. Compared with patients exposed to water with an arsenic concentration ≤10 mcg/L, patients exposed to water containing arsenic concentrations of 10 to 50 mcg/L, 50 to 100 mcg/L, and &gt;100 mcg/L had adjusted relative risks of bladder cancer development of 1.9, 8.2, and 15.3, respectively. Additionally, younger age at exposure is associated with increased mortality rates from bladder cancer in adulthood [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/2957.html" rel="external">"Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder", section on 'Drinking water'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin cancer</strong> – Ingestion of inorganic arsenic increases the risk of latent development of skin cancers [<a href="#rid31">31,67</a>]. Bowen disease (squamous cell carcinoma in situ) arises from arsenic-induced hyperkeratotic warts  (<a class="graphic graphic_picture graphicRef57673" href="/z/d/graphic/57673.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef78647" href="/z/d/graphic/78647.html" rel="external">picture 2</a>). Basal cell carcinomas arise from cells not associated with hyperkeratinization. In a cohort study in Bangladesh, patients who were exposed to water with an arsenic concentration between 175 and 864 mcg/L were five times more likely to develop pre-malignant skin lesions compared with those exposed to well water with a concentration ≤8 mcg/L [<a href="#rid77">77</a>]. Inorganic arsenic exposure increases the risk of skin cancer even in the absence of skin pigmentary changes [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Chronic arsenic exposure'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney cancer</strong> – Arsenic in drinking water may be associated with transitional cell cancers of the renal pelvis and ureter [<a href="#rid67">67,79</a>]. In one case-control study, the odds ratios for transitional cell cancer were 1.0, 5.7, and 11.1 for median arsenic water concentrations of 60, 300, and 860 mcg/L, respectively [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/2987.html" rel="external">"Malignancies of the renal pelvis and ureter", section on 'Environmental causes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver</strong> <strong>cancer </strong>– Arsenic exposure is believed to increase the risk of hepatic angiosarcomas, but it does not appear to be associated with hepatocellular carcinoma [<a href="#rid67">67,80</a>]. (See  <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Angiosarcoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate cancer</strong> – Most, but not all studies, have found an association between arsenic exposure in drinking water and increased prostate cancer risk [<a href="#rid67">67,69</a>]. Studies from Taiwan have found some evidence of a dose–response relationship, but there is not a consistent association in data from South America [<a href="#rid67">67</a>]. A meta-analysis of 12 studies (over 8 million patients) found arsenic exposure (as assessed by water, soil, or urinary measurements or self-reported questionnaire) was associated with increased prostate cancer risk (relative risk [RR] 1.18, 95% CI 1.06 – 1.3) [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/6938.html" rel="external">"Risk factors for prostate cancer", section on 'Environmental carcinogens'</a>.) </p><p></p><p class="headingAnchor" id="H9"><span class="h2">Dermatologic</span><span class="headingEndMark"> — </span>Various arsenic-related skin lesions have been described in the West Bengal and Bangladesh chronic poisonings [<a href="#rid17">17,23,24,82</a>]. Epidemiological studies suggest that skin lesions occur in individuals consuming water with arsenic concentrations generally &gt;100 mcg/L and usually for at least six months [<a href="#rid16">16,78</a>]. Data from 10,182 patients with well-water arsenic exposure followed for six years in the HEALS study showed a dose-dependent increased risk of skin lesions [<a href="#rid83">83</a>]. Risk was increased with well water arsenic concentrations as low as 50 mcg/L, as well as in males and older individuals. The risk of developing skin lesions persisted for up to several years despite decreasing exposure. </p><p>The following skin lesions can develop in chronic arsenic toxicity:</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperpigmentation (ie, melanosis) or hypopigmentation can be an early manifestation  (<a class="graphic graphic_picture graphicRef140127" href="/z/d/graphic/140127.html" rel="external">picture 3</a>). Various pigmentary changes have been described, including diffuse melanosis, freckled raindrop pattern  (<a class="graphic graphic_picture graphicRef141017" href="/z/d/graphic/141017.html" rel="external">picture 4</a>), leukomelanosis (depigmented macules on normal skin or on a hyperpigmented background)  (<a class="graphic graphic_picture graphicRef141019" href="/z/d/graphic/141019.html" rel="external">picture 5</a>), dyschromia, and mucosal pigmentation [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arsenic keratosis is a characteristic marker of more advanced stages of chronic arsenic toxicity [<a href="#rid16">16,78</a>]. These multiple premalignant lesions are firm, punctate papules which may coalesce into scaly, erythematous, hyperpigmented, or verrucous plaques  (<a class="graphic graphic_picture graphicRef57673" href="/z/d/graphic/57673.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef141020" href="/z/d/graphic/141020.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef78647" href="/z/d/graphic/78647.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef120222" href="/z/d/graphic/120222.html" rel="external">picture 7</a>). These commonly occur on the palms and soles, but can also occur on the dorsum of extremities, trunk, genitalia, and eyelids. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral vascular disease with associated gangrene, called "Blackfoot" disease, has been described [<a href="#rid84">84-86</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eczematous lesions have also been described. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin carcinomas are discussed above. (See <a class="local">'Cancer'</a> above.)</p><p></p><p>Chronic skin lesions that have delayed onset following acute arsenic poisoning include maculopapular eruptions (sometimes in intertriginous areas), nail changes (Mees' or Beau's lines  (<a class="graphic graphic_picture graphicRef90474" href="/z/d/graphic/90474.html" rel="external">picture 8</a>)), and periungual pigmentation. </p><p class="headingAnchor" id="H10"><span class="h2">Neurologic</span><span class="headingEndMark"> — </span>A symmetrical sensorimotor polyneuropathy is one of the most prominent symptoms of arsenic poisoning and can develop one to three weeks after acute high-dose poisoning or insidiously from chronic low-level exposures. Electrophysiological findings of arsenic neuropathy typically suggest a distal motor and sensory axonopathy [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">"Overview of nerve conduction studies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Numbness and paresthesias </strong>– Sensory symptoms tend to develop first and predominate, starting with numbness and tingling, particularly in the soles of the feet and then later in the hands [<a href="#rid6">6,87,88</a>]. An early sign on physical examination is diminished vibratory sense. </p><p></p><p class="bulletIndent1">Milder forms of arsenic polyneuropathy may only have numbness and paresthesias and may even be subclinical. Studies of smelting factory workers exposed to inorganic arsenic compared with controls found an inverse correlation between cumulative absorption of arsenic and nerve conduction velocities (in the absence of signs or symptoms), as well as increased risk of clinical neuropathy [<a href="#rid89">89,90</a>]. </p><p></p><p class="bulletIndent1">A case series of 40 individuals with skin lesions and elevated arsenic in biological samples who were exposed to arsenic-contaminated water in India found that 21 were diagnosed with clinical neuropathy [<a href="#rid23">23</a>]. Most of the cases presented with distal paresthesias and distal hypesthesias in a stocking and glove distribution, and in those most severely affected, followed by limb pain and diminished or absent deep tendon reflexes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pain</strong> <strong>and weakness</strong> – In more severe neuropathy, pain can be intense and provoked with even light touch so that affected persons are unable to walk because of intense burning pain in the soles [<a href="#rid88">88</a>]. Cramping in the calves is another common symptom.</p><p></p><p class="bulletIndent1">Progressive symptoms may then develop in a stocking/glove distribution with decreased pain, decreased sensation of touch and temperature, and symmetrical weakness, along with decreased deep tendon reflexes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recovery </strong>– Neuropathy, especially if mild, may improve and/or recover in the long-term following cessation of arsenic exposure [<a href="#rid91">91,92</a>]. A case-control study of 30 patients with arsenical dermatoses found improvement in neuropathy (both symptomatic and nerve conduction velocities reported similar to controls) a decade following the drinking water exposure [<a href="#rid93">93</a>]. </p><p></p><p>Case reports of chronic arsenic exposure associated with encephalopathy, described as cognitive impairment, disorientation, hallucinations, agitations, and memory problems [<a href="#rid94">94-96</a>]. However, it is not clear from these reports whether symptoms are solely from arsenic or from other potential work exposures or psychiatric issues [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Cardiovascular</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>QTc prolongation and ventricular dysrhythmias</strong> – QTc prolongation and ventricular dysrhythmias have been reported in patients with acute promyelocytic leukemia treated with <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> and in individuals chronically exposed to arsenic in drinking water [<a href="#rid98">98-100</a>]. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a> and  <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension</strong> – Chronic exposure to arsenic has been associated with development of hypertension [<a href="#rid101">101-103</a>]. Studies in Bangladesh found a dose-response relationship between arsenic exposure and urine arsenic concentrations and the prevalence of hypertension [<a href="#rid103">103,104</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease and mortality </strong>– Chronic exposure to arsenic has been associated with increased risk of developing cardiovascular disease (eg, coronary artery disease, cerebrovascular disease, and peripheral artery disease) [<a href="#rid105">105</a>]. In a study of Colorado residents, lifetime exposure to low-level inorganic arsenic in drinking water was associated with a dose-dependent increased risk of coronary artery disease [<a href="#rid106">106</a>]. However, epidemiologic studies have not demonstrated the association of arsenic with cardiovascular disease in all populations [<a href="#rid107">107</a>]. </p><p></p><p class="headingAnchor" id="H865401332"><span class="h2">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver disease</strong> – A study in Mexico found increased bilirubin and alkaline phosphatase concentrations in people exposed to arsenic in drinking water [<a href="#rid108">108</a>]. A study of 248 people in India with chronic arsenic toxicity found that hepatomegaly was present in 77 percent; in those who underwent liver biopsy, noncirrhotic portal fibrosis (ie, idiopathic noncirrhotic portal hypertension) was the predominant finding [<a href="#rid109">109</a>]. (See  <a class="medical medical_review" href="/z/d/html/3580.html" rel="external">"Noncirrhotic portal hypertension", section on 'Idiopathic noncirrhotic portal hypertension/Porto-sinusoidal vascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes</strong> – Arsenic exposure may be associated with the development of type II diabetes mellitus [<a href="#rid110">110,111</a>]. Some studies have found a dose-response relationship between exposure to arsenic in drinking water and the risk of diabetes [<a href="#rid110">110,112</a>], whereas a large population-based cross-sectional study did not demonstrate an association between arsenic concentrations in well water and prevalence of diabetes [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory</strong> – Arsenic exposure is associated with a dose-dependent increase in respiratory symptoms (cough, dyspnea, hemoptysis) and decrease in lung function [<a href="#rid70">70,114,115</a>]. The risk of developing bronchiectasis is exacerbated by early-life arsenic exposure. (See <a class="local">'Pediatrics'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologic</strong> – Some patients who survive acute poisoning and those with high-dose chronic poisoning have been reported to develop bone marrow suppression with pancytopenia [<a href="#rid116">116</a>]. The anemia is typically normocytic, but in rare cases, it has been megaloblastic. Karyorrhexis and basophilic stippling has also been occasionally reported [<a href="#rid117">117,118</a>]. </p><p></p><p class="headingAnchor" id="H3721151951"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1567218792"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>The evaluation of a patient with possible chronic arsenic toxicity starts with obtaining a detailed history focused on uncovering potential sources of inorganic arsenic exposure and assessing for signs and symptoms characteristic of arsenic toxicity. (See <a class="local">'Sources of exposure and regulatory limits'</a> above and <a class="local">'Clinical features and latent effects of chronic exposure'</a> above.) </p><p>If suspecting a patient has had an occupational inorganic arsenic exposure, we ask about the circumstances and timing of the exposure, whether personal protective gear was being worn, and if the exposure is ongoing. We inquire whether actions have already been taken to assess and control the exposure and review any reports if available. Obtaining a thorough history is particularly important given the limitations of biological testing for arsenic. (See <a class="local">'Arsenic concentrations'</a> below.)</p><p>The process of obtaining a general exposure history is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2749.html" rel="external">"Overview of occupational and environmental health", section on 'Occupational and environmental history'</a>.)</p><p class="headingAnchor" id="H2234272948"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of chronic arsenic toxicity is suspected in a patient with symptoms or signs associated with chronic toxicity, such as skin lesions, sensorimotor polyneuropathy, or abnormal liver enzymes, especially if they report a potential environmental or occupational exposure. (See <a class="local">'Clinical features and latent effects of chronic exposure'</a> above.)</p><p>The diagnosis of chronic arsenic toxicity is made in a patient with characteristic signs and symptoms and a confirmed exposure if possible. An exposure can be confirmed by any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Biological sample with elevated inorganic arsenic concentration. Urine is the most commonly used sample, but nail or hair testing can confirm an exposure that occurred within months if measured by a reliable laboratory. However, it is important to note the timing of the biological testing. (See <a class="local">'Arsenic concentrations'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Soil, air, or water sample with elevated arsenic concentration, determined by a reliable laboratory (eg, testing water if from a private well or obtaining testing report if from a public water source). (See <a class="local">'Environmental (eg, drinking water)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An exposure history to a confirmed source of arsenic (eg, drinking contaminated well water in Bangladesh). (See <a class="local">'History and examination'</a> above.)</p><p></p><p class="headingAnchor" id="H2336255443"><span class="h2">Arsenic concentrations</span><span class="headingEndMark"> — </span>Biological samples used to obtain arsenic concentrations include urine, blood, hair, and fingernail. Environmental sources (eg, drinking water) can also be tested for arsenic. (See <a class="local">'Environmental (eg, drinking water)'</a> below.)</p><p>Urine is the most commonly used biological sample, but each has limitations that impact interpretation of results. If the exposure was recent and/or ongoing, we obtain urine arsenic concentration and speciation and urine creatinine concentration. In a patient with concern for chronic arsenic exposure, we do not obtain a blood arsenic concentration because arsenic is rapidly cleared (two to three hours) from blood and distributed to other tissues and arsenic speciation cannot be performed on blood samples. Blood arsenic is only useful for assessing very recent exposure, usually in the setting of an acute poisoning, and for monitoring during chelation therapy.  </p><p class="headingAnchor" id="H1604615810"><span class="h3">Urine</span><span class="headingEndMark"> — </span>Urine arsenic is a good measure of current or recent exposure but not for remote exposure because arsenic is rapidly excreted. After a single exposure, half of the arsenic is eliminated over the first day and most of the rest over the next three days [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Speciation</strong> – Urine arsenic testing should be speciated, with specific assessment of the inorganic species, in order to avoid misdiagnosis of arsenic poisoning in a patient exposed to non-toxic organic forms [<a href="#rid10">10,119</a>]. Unless otherwise requested, many laboratories do not reflexively perform speciation and will usually report only total arsenic. Thus, when we order a total urine arsenic test, we also request reflex speciation if the total concentration is elevated. </p><p></p><p class="bulletIndent1">Laboratories report the results of speciation in different ways: some will report total arsenic and inorganic species, while others will report inorganic, methylated, and organic (with "organic" implying the relatively non-toxic arsenobetaine and other fish arsenicals). The laboratory may report individual concentrations of inorganic arsenic, methylated metabolites monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA), as well as the total arsenic. If the total urinary arsenic is elevated, but there are little to no inorganic species detected, the urine arsenic was most likely derived from organic arsenic species.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Issues with seafood consumption</strong> – While some clinicians will advise refraining from eating any fish, shellfish, or seaweed for two to three days<strong> </strong>prior to testing, we feel it is generally unnecessary as speciation of elevated urinary arsenic can distinguish between the different arsenical compounds. There may be other dietary sources of arsenic (such as some mushrooms), which is another reason we favor speciation. Presence of the relatively non-toxic "fish arsenic" (eg, arsenobetaine) increases total arsenic urine concentrations; even a single meal of fish can increase total urine arsenic by more than 1000 mcg/L [<a href="#rid9">9,10</a>]. However, seafood consumption should not increase inorganic arsenic concentrations. Additionally, individuals without fish or seafood intake can have elevated total arsenic concentrations (without inorganic species) since other foods, such as wild mushrooms, can contain organic arsenic such as arsenobetaine [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spot urine samples</strong> – In adults, spot urine arsenic concentrations are sufficient for most circumstances, particularly useful for occupational biomonitoring, and obviate the need for 24-hour testing in the ambulatory setting. However, a spot urine arsenic concentration should be corrected for urine concentration by dividing by a simultaneously obtained urine creatinine concentration (resulting in units of mcg arsenic [As]/g creatinine). This also allows for standardization and for comparison of samples if urine arsenic is collected as a part of surveillance program. A very low urine creatinine also suggests the spot sample may be too dilute for an accurate determination. Urine creatinine may not reflect hydration status in individuals with chronic kidney disease (eg, high serum creatinine with lower urine creatinine).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>24-hour urine sample</strong> – Although a 24-hour urine collection for arsenic is more accurate, it is much less convenient than a spot urine sample. The 24-hour collection is more appropriate for monitoring of inpatients being chelated for arsenic poisoning. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation of results</strong> – There is no "normal" concentration of urinary arsenic since arsenic is not a normal constituent of the human body. Since some exposure to arsenic from daily life is expected, we interpret the patient's results by comparing to the population background mean concentrations. </p><p></p><p class="bulletIndent1">The Centers for Disease Control and Prevention measures a random sample of United States participants in the National Health and Nutrition Examination Survey and tests blood and urine for various chemicals or metabolites, such as arsenic [<a href="#rid120">120,121</a>]. Between 2017-2018, mean total urine arsenic (and creatinine corrected) for adults was approximately 6 mcg/L (7 mcg As/g creatinine) and the<sup> </sup>95<sup>th</sup> percentile geometric mean was 67 mcg/L (60 mcg As/g creatinine). The mean for inorganic arsenic (sum of arsenic acid, arsenous acid, DMA, MMA) for adults was approximately 4 mcg/L (5 mcg As/g creatinine) and the<sup> </sup>95<sup>th</sup> percentile geometric mean was 14 mcg/L (15 mcg As/g creatinine). For comparison, in acutely symptomatic patients, total urine arsenic concentrations are usually &gt;1000 mcg/L.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biological monitoring</strong> – Some professional organization suggest performing biological monitoring tests to ensure workers do not have exposures that exceed acceptable levels. The "acceptable levels" in the urine are usually based upon correlations of the urine test with the allowable (or regulated) air level. Surveillance for occupational arsenic exposure is usually done with measurements of spot urine arsenic and creatinine, sometimes timed to be collected after a shift. The American Conference of Governmental Industrial Hygienists (ACGIH) recommends testing for urine arsenic (inorganic arsenic and methylated metabolites) at the end of the work week, and set a biological exposure index (BEI) of 35 mcg/L, which correlates with an air concentration limit of 10 mcg/m<sup>3</sup> [<a href="#rid3">3</a>]. However, acceptable limits vary by country and agency; for example in Germany (DFG) it is 15 mcg/L and the European Chemicals Agency (ECHA) set it at 10 mcg/L [<a href="#rid122">122</a>]. Repeat testing is performed pending the circumstances of the exposure or occupational regulations.</p><p></p><p class="headingAnchor" id="H1892613001"><span class="h3">Hair and nail</span><span class="headingEndMark"> — </span>Determination of arsenic in hair and nails is most useful in epidemiologic studies performed to evaluate environmental exposures of populations to inorganic arsenic. Hair and fingernails may be good indicators for exposure to inorganic arsenic during their growth period (hair grows at 0.4 mm per day, while nails grow at a rate of 0.1 mm per day) since inorganic arsenic (to a much greater extent than organic arsenic) binds to protein and is deposited in hair and nails. In a patient with signs or symptoms suggestive of arsenic toxicity thought due to past exposures, careful collection of appropriate hair samples (ideally from areas of slow growth such as pubic hair) or nails can be analyzed for arsenic. Nail analysis usually requires clipping as much as possible from all digits (either fingernails <strong>or </strong>toenails). To collect the samples, particularly for pubic or axillary hair, we provide the patient with scissors and collection bottle, and the person can collect privately in the examination room, which may prevent contamination from the home environment.</p><p>Samples should be sent to a clinical laboratory experienced with metal testing and the testing should be only for arsenic rather than multiple elements. Results from hair and nail testing can be unreliable because of lack of standardization of analyses techniques. For example, commercial laboratory hair analyses for multiple elements including arsenic have been found to be highly inaccurate [<a href="#rid123">123,124</a>]. Also, since removing exogenous arsenic from hair is very difficult, testing results may not be meaningful if air or dust containing arsenic comes into contact with hair or if showering with arsenic contaminated water [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H1722251104"><span class="h3">Environmental (eg, drinking water)</span><span class="headingEndMark"> — </span>If a patient or clinician is concerned for an arsenic exposure from drinking water, we either ask the patient to test the water if from a private well or obtain a report of testing if from a public water source. The local department of public health or the regional department of environmental protection can sometimes advice a reliable laboratory that performs water testing. If there is a known source of contamination (eg, mine), governmental agencies may already be testing local water supplies. As noted above, current United States and World Health Organization guidelines recommend arsenic water concentrations be less than 10 mcg/L to reduce the risk of arsenic-related cancer. (See <a class="local">'Drinking water'</a> above.)</p><p>Examination of an environmental site can be performed by the Environmental Protection Agency (EPA). Examination of an occupational site can be performed by the Occupational Safety and Health Administration (OSHA). In addition to government agencies, private consultants (eg, certified industrial hygienists) can also examine sites, but it is helpful to have this coordinated by an occupational/environmental medicine specialist. (See <a class="local">'Occupational/environmental medicine clinicians'</a> below.)</p><p class="headingAnchor" id="H21"><span class="h2">Post-diagnostic and ancillary testing</span><span class="headingEndMark"> — </span>In a patient with a remote acute exposure (possibly weeks to months prior) with an elevated inorganic arsenic concentration, or with signs and symptoms consistent with chronic toxicity, we obtain a complete blood count, tests of kidney and liver function, electrocardiogram (to evaluate for QTc interval prolongation), and a urinalysis. </p><p>In a patient with signs or symptoms of peripheral neuropathy and objective evidence is needed, we refer to a neurologist for nerve conduction studies (NCS) and for further evaluation of other potential causes of peripheral neuropathy. We do not routinely obtain NCS since these do not typically impact management decisions. (See  <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">"Overview of nerve conduction studies"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1562828577"><span class="h2">Preventing ongoing exposure</span><span class="headingEndMark"> — </span>The most important steps in the management of chronic arsenic poisoning are identification of the source of exposure, removal from the exposure (or marked reduction), and elimination of ongoing and future exposure to inorganic arsenic. </p><p>Arsenic is generally not absorbed from intact skin, and skin contamination from chronic exposure in the non-occupational setting usually does not occur. In a patient with recent skin exposure, as might occur in an occupational setting, arsenic can be removed with soap, water and scrubbing. Care should be taken to protect the contaminated person or treating clinician (ie, wearing personal protection to prevent inhalation of any aerosol), to avoid contaminating the surroundings, and to properly dispose of any contaminated fluids as a hazardous material. </p><p>A patient who reports or is identified to have an occupational arsenic exposure should be advised about contacting the government agency responsible for their workplace hazards, especially if the exposure is not being addressed. In the Unites States, the Occupational Safety and Health Administration (OSHA) can be contacted via phone (800-321-6742) or a complaint can be filed on their <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.osha.gov%2Fcontactus&amp;token=mJ2XuLqdLLe0%2BA8rZisyxkMSVRyTz5xP%2FEDoeymAKNoq9oLgI2GHb2KDzpOd%2BK8d&amp;TOPIC_ID=2778" target="_blank">website</a>. The patient can also be advised about consulting an occupational medicine specialist or regional poison control center. (See <a class="local">'Occupational/environmental medicine clinicians'</a> below and <a class="local">'Regional poison control centers'</a> below.)</p><p>Patients should be instructed not to cook with arsenic-contaminated water and never to burn pressure-treated wood in fireplaces or campfires.</p><p class="headingAnchor" id="H5643077"><span class="h2">Chelation not beneficial for past chronic exposure</span><span class="headingEndMark"> — </span>In a patient with chronic arsenic exposure, we do not routinely administer chelation therapy. There are few studies, with significant limitations, regarding the efficacy of chelation therapy in the setting of chronic toxicity [<a href="#rid125">125</a>]. These studies have demonstrated inconsistent results, and improvement in symptoms has been mostly subjective [<a href="#rid126">126,127</a>]. Although chelation therapy increases arsenic excretion and possibly lowers arsenic concentration in some tissues, it is unclear whether this results in less morbidity or mortality in the setting of chronic arsenic toxicity. Chelators mobilize metals and redistribute them to body tissue, ideally increasing excretions, but the effects of redistribution are not completely understood. Chelators (ie, <a class="drug drug_general" data-topicid="9367" href="/z/d/drug information/9367.html" rel="external">dimercaprol</a> [BAL], succimer [DMSA], unithiol [DMPS])  (<a class="graphic graphic_table graphicRef69443" href="/z/d/graphic/69443.html" rel="external">table 1</a>) also have adverse effects and can increase excretion of other beneficial metals, such as zinc and copper. Additionally, the efficacy of chelators decreases as the time since exposure increases. </p><p>Conversely, chelator therapy is used in patients with acute arsenic toxicity, which is beyond the scope of this topic. </p><p class="headingAnchor" id="H2580078125"><span class="h2">Dermatologic lesions</span><span class="headingEndMark"> — </span>Arsenic-induced skin cancers, Bowen disease, and premalignant keratosis can be treated with various therapies that are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5339.html" rel="external">"Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"</a> and  <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">"Treatment and prognosis of basal cell carcinoma at low risk of recurrence"</a>.)</p><p>Currently published evidence suggests that effective therapies for other arsenic-induced skin lesions are lacking [<a href="#rid78">78</a>]. Keratolytic agents (eg, salicylic acid), retinoids, photodynamic therapy, and nicotinamide have been studied with inconclusive benefits. Therapies for porokeratotic lesions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/13721.html" rel="external">"Porokeratosis", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1213228910"><span class="h2">Referral to specialist</span><span class="headingEndMark"> — </span>Clinicians involved in the care of patients with arsenic poisoning, or patients who have questions about arsenic exposures, may find it helpful to consult with occupational/environmental medicine clinicians who can assist in the diagnosis of arsenic poisoning, in the arrangement for environmental/work site evaluations and interventions, and in evaluations for worker compensation. Occupational/environmental medicine clinicians can also help with the decision for chelation therapy and administration of appropriate therapy. (See <a class="local">'Occupational/environmental medicine clinicians'</a> below.)</p><p>Patients with arsenic keratosis and/or skin cancers should be evaluated and closely followed by a dermatologist.</p><p class="headingAnchor" id="H3377181245"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H638306136"><span class="h2">Pediatrics</span><span class="headingEndMark"> — </span>In general, children are more susceptible than adults to toxicants (including arsenic), for a variety of reasons such as more opportunities for exposure from increased hand-to-mouth behavior, breathing closer to the ground, differences in metabolism, and greater sensitivity of the developing nervous system to toxic insults [<a href="#rid128">128,129</a>]. Compared with adults, children have less capacity for methylation, which is important for detoxification of inorganic arsenic [<a href="#rid129">129</a>]. In children, latent effects may include neurobehavioral changes. </p><p>Early-life (ie, in utero and childhood) exposure to high arsenic levels in a contaminated water supply in Chile was associated with increased risk of developing bladder, laryngeal, and lung cancer, as well as bronchiectasis, three to four decades after the exposure [<a href="#rid70">70</a>]. Children born during the decade of contamination and exposed in utero or between the ages of 1 to 10 had a 12-fold increase or a 5-fold increase in mortality from bronchiectasis, respectively. Children with exposure beginning at birth had a 16-fold increase in mortality from bladder cancer.</p><p>To reduce the exposure to potential arsenic-contaminated rice products, the American Academy of Pediatrics advises feeding babies a variety of foods and increasing dietary intake of foods made from wheat and oats [<a href="#rid130">130-132</a>]. The US Pediatric Environmental Health Specialty Units advise limiting consumption of foods with high arsenic content, limiting rice milk in children younger than 54 months of age, reducing intake of foods containing high amounts of brown rice syrup, and rinsing rice prior to cooking [<a href="#rid133">133</a>]. </p><p class="headingAnchor" id="H39875236"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Since inorganic arsenic crosses the placenta, there is a potential for adverse reproductive and developmental outcomes. There is evidence of increased infant mortality, spontaneous abortions, stillbirths, and pre-term births associated with maternal arsenic exposure [<a href="#rid134">134-137</a>]. (See  <a class="medical medical_review" href="/z/d/html/111468.html" rel="external">"Occupational and environmental risks to reproduction in females: Specific exposures and impact", section on 'Reproductive health impact'</a>.)</p><p class="headingAnchor" id="H2386524299"><span class="h2">Nursing mothers</span><span class="headingEndMark"> — </span>Limited data suggest that arsenic concentrations in breast milk are low even in women exposed to high levels of environmental arsenic [<a href="#rid138">138-141</a>]. Thus, prolonged breastfeeding can protect infants and toddlers from arsenic toxicity in regions with high concentrations of arsenic in the drinking water.</p><p class="headingAnchor" id="H877047050"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2689013814"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H4291760466"><span class="h2">Regional Pediatric Environmental Health Specialty Units</span><span class="headingEndMark"> — </span>For pediatric arsenic exposures and poisonings in the United States, the (PEHSUs) are a national network of experts in the prevention, diagnosis, management, and treatment of health issues that arise from environmental exposures from preconception through adolescence.</p><p class="headingAnchor" id="H2553954865"><span class="h2">Occupational/environmental medicine clinicians</span><span class="headingEndMark"> — </span>Clinicians specializing in Occupational and Environmental Medicine can be located by contacting the Association of Occupational and Environmental Clinics (AOEC), a group of occupational medicine clinics (frequently academically affiliated) with board-certified occupational medicine physicians (phone: 202-347-4976; website: <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.aoec.org%2F&amp;token=ZG1%2BPwRUU1rBex5m1Ml5lfAIA%2B4JXtDbEUxLiSfLiuI%3D&amp;TOPIC_ID=2778" target="_blank">www.aoec.org</a>), or the American College of Occupational and Environmental Medicine Physicians (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.acoem.org%2F&amp;token=ppy6PCRiE9HJgc%2Bl6sW1nQKlj1q8HKu%2BZ%2BFCLHozlig%3D&amp;TOPIC_ID=2778" target="_blank">www.acoem.org</a>).</p><p class="headingAnchor" id="H4145670545"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112690.html" rel="external">"Society guideline links: Lead and other heavy metal poisoning"</a>.)</p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology of arsenic toxicity</strong> – Arsenic toxicity can vary greatly depending on the chronicity and dose of exposure and the chemical properties of the arsenical compound (eg, valence, complexed structures). Trivalent arsenicals, both inorganic and organic metabolites, are considered the most toxic. Elemental arsenic and some organic forms of arsenic such as arsenobetaine are likely non-toxic. (See <a class="local">'Pathophysiology of arsenic toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources of exposure</strong> – Arsenic is a naturally occurring element found in the earth's crust and within numerous ores. Exposures can occur from natural sources, occupational sources, dietary intake, drinking water, and include the following (see <a class="local">'Sources of exposure and regulatory limits'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Well water contaminated from industrial, hazardous waste, superfund sites, or natural leaching from soil and rocks (see <a class="local">'Drinking water'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Use and manufacture of arsenic-containing pesticides</p><p class="bulletIndent2"><span class="glyph">•</span>Fossil fuel combustion</p><p class="bulletIndent2"><span class="glyph">•</span>Inhaled dust from smelting and refining</p><p class="bulletIndent2"><span class="glyph">•</span>Metallurgy, semiconductor, decorative glass-making, and mining industries</p><p class="bulletIndent2"><span class="glyph">•</span>Dietary ingestion (typically originates from contaminated water or soil-derived foods such as rice) (see <a class="local">'Dietary ingestion'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Contact with pressure-treated wood </p><p class="bulletIndent2"><span class="glyph">•</span>Therapeutical arsenicals, such as <a class="drug drug_general" data-topicid="126253" href="/z/d/drug information/126253.html" rel="external">melarsoprol</a> (treatment for trypanosomiasis) and <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">arsenic trioxide</a> (treatment for acute promyelocytic leukemia) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of chronic toxicity</strong> – Clinical features of chronic toxicity can occur after low- to moderate-level, prolonged exposure to arsenic and cause toxicity that develops over months to years. These can have an insidious onset and thus be difficult to recognize and diagnose. Latent effects from exposure refers to the malignancies, skin changes, cardiac effects, and neurobehavioral changes (which may be seen in children) that can develop years to decades after an acute or chronic exposure, even if the exposure has ceased. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1">Clinical features of chronic toxicity and latent effects include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cancer</strong> – Inorganic arsenic is a recognized carcinogen and associated with increased risk of developing cancers of the skin (Bowen disease and basal cell carcinoma), bladder, kidney (transitional cell), lung, liver (hepatic angiosarcomas), and prostate. (See <a class="local">'Cancer'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dermatologic</strong> – Skin findings can include hyperpigmentation, hypopigmentation, kyperkeratoses and scaling (particularly the palms and soles), and gangrene ("Blackfoot" disease). Delayed skin manifestations can develop after acute poisoning and include maculopapular eruptions (sometimes in intertriginous areas), nail changes (Mees' or Beau's lines)  (<a class="graphic graphic_picture graphicRef90474" href="/z/d/graphic/90474.html" rel="external">picture 8</a>), and periungual pigmentation. (See <a class="local">'Dermatologic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic </strong>– A symmetrical sensorimotor polyneuropathy is one of the most prominent symptoms of arsenic poisoning and can develop one to three weeks after acute high-dose poisoning or insidiously from chronic low-level exposures. The neuropathy can be very painful and result in weakness. (See <a class="local">'Neurologic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular</strong> – Effects can include QTc prolongation (causing ventricular dysrhythmias), hypertension, and increased risk of developing cardiovascular disease (eg, coronary artery disease, cerebrovascular disease, and peripheral artery disease) and cardiovascular-related death. (See <a class="local">'Cardiovascular'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Others</strong> – Liver injury, type II diabetes mellitus, bronchiectasis, and anemia have potentially been associated with arsenic exposure. (See <a class="local">'Others'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation </strong>– The evaluation of a patient with possible chronic arsenic toxicity starts with obtaining a detailed history focused on uncovering potential sources of inorganic arsenic exposure and assessing for signs and symptoms characteristic of arsenic toxicity. (See <a class="local">'History and examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – The diagnosis of chronic arsenic toxicity is made in a patient with characteristic signs and symptoms and a confirmed exposure, such as elevated concentrations in biological samples, soil, air, and water sample with elevated concentrations, or a history of exposure to a known or documented source of arsenic. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urine arsenic concentrations</strong> – A spot urine arsenic concentration (along with a urine creatinine to correct for the concentration) is sufficient for most circumstances. Although concentrations greater ≥50 mcg/L or 100 mcg As/g creatinine in the absence of recent fish, seaweed, or shellfish intake strongly suggests arsenic exposure/poisoning, no conclusion can be drawn until fractionated testing confirms the presence of inorganic-related arsenic species. For more accurate assessment, at the time of ordering, clinicians should request specific measurement of inorganic arsenic species if the total level is elevated. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ancillary testing</strong> – In patients with a remote acute exposure (possibly weeks to months prior), an elevated arsenic concentration, or signs and symptoms consistent with chronic toxicity, we obtain a complete blood count, tests of kidney and liver function, electrocardiogram (to evaluate for QTc prolongation), and a urinalysis. If a patient has signs or symptoms of peripheral neuropathy, nerve conduction studies should be obtained if objective documentation is needed or to exclude another cause of neuropathy. (See <a class="local">'Post-diagnostic and ancillary testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The most important step in the management of chronic inorganic arsenic poisoning is removal from the exposure and elimination of ongoing and future exposure. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1">We do not routinely administer chelation therapy to a patient with chronic arsenic exposure or toxicity since there is insufficient evidence of benefit. (See <a class="local">'Chelation not beneficial for past chronic exposure'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Mundy SW. Arsenic. In: Goldfrank's Toxicologic Emergencies, 11th ed, Nelson L, Hoffman R, Howland MA, et al (Eds), McGraw-Hill Education, 2019. p.1237.</li><li class="breakAll">World Health Organization. Exposure to arsenic: A major public concern. 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/329482/WHO-CED-PHE-EPE-19.4.1-eng.pdf (Accessed on January 25, 2022).</li><li><a class="nounderline abstract_t">Baker BA, Cassano VA, Murray C, ACOEM Task Force on Arsenic Exposure. Arsenic Exposure, Assessment, Toxicity, Diagnosis, and Management: Guidance for Occupational and Environmental Physicians. J Occup Environ Med 2018; 60:e634.</a></li><li><a class="nounderline abstract_t">Seixas J, Atouguia J, Josenando T, et al. Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association. Trop Med Infect Dis 2020; 5.</a></li><li><a class="nounderline abstract_t">Taylor V, Goodale B, Raab A, et al. Human exposure to organic arsenic species from seafood. Sci Total Environ 2017; 580:266.</a></li><li class="breakAll">Windebank AJ. Arsenic. In: Experimental and Clinical Neurotoxicology, Spencer PS, Schaumburg HH (Eds), Oxford University Press, New York 2000. p.203.</li><li class="breakAll">Fowler BA, Selene CH, Chou RJ, et al. Arsenic. In: Handbook on the Toxicology of Metals, 4th ed, Nordberg GF, Fowler BA, Nordberg M (Eds), Academic Press, San Diego 2015. p.581.</li><li><a class="nounderline abstract_t">Aposhian H. Biochemical toxicology of arsenic. Rev Biochem Toxicol 1989; 10:265.</a></li><li class="breakAll">Lauwerys RR, Hoet P. Industrial Chemical Exposure - Guidelines for Biological Monitoring, Lewis Publishers, Boca Raton 2000.</li><li><a class="nounderline abstract_t">Orloff K, Mistry K, Metcalf S. Biomonitoring for environmental exposures to arsenic. J Toxicol Environ Health B Crit Rev 2009; 12:509.</a></li><li class="breakAll">Centers for Disease Control and Prevention. National Biomonitoring Program. Biomonitoring summary: Arsenic. Available at: www.cdc.gov/biomonitoring/Arsenic_BiomonitoringSummary.html (Accessed on February 08, 2022).</li><li><a class="nounderline abstract_t">Bailey KA, Smith AH, Tokar EJ, et al. Mechanisms Underlying Latent Disease Risk Associated with Early-Life Arsenic Exposure: Current Research Trends and Scientific Gaps. Environ Health Perspect 2016; 124:170.</a></li><li><a class="nounderline abstract_t">Balakumar P, Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc Toxicol 2009; 9:169.</a></li><li class="breakAll">Agency for Toxic Substances and Disease Registry. Toxicological Profile for Arsenic. U.S. Department of Health &amp; Human Services, Public Health Service 2007. Available at: https://www.atsdr.cdc.gov/ToxProfiles/tp2.pdf (Accessed on January 11, 2023).</li><li class="breakAll">ATSDR. Addendum to the Toxicological Profile for Arsenic. Atlanta, Georgia: U.S. Department of Health and Human Services; 2016. Available at: https://www.atsdr.cdc.gov/toxprofiles/Arsenic_addendum.pdf (Accessed on January 13, 2023).</li><li><a class="nounderline abstract_t">Naujokas MF, Anderson B, Ahsan H, et al. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect 2013; 121:295.</a></li><li class="breakAll">National Research Council. Arsenic in Drinking Water, 2001 Update. National Academy Press; Washington, DC 2001.</li><li class="breakAll">World Health Organization. Fact sheets: Arsenic. 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/arsenic (Accessed on May 30, 2020).</li><li><a class="nounderline abstract_t">Monteiro De Oliveira EC, Caixeta ES, Santos VSV, Pereira BB. Arsenic exposure from groundwater: environmental contamination, human health effects, and sustainable solutions. J Toxicol Environ Health B Crit Rev 2021; 24:119.</a></li><li><a class="nounderline abstract_t">Podgorski J, Berg M. Global threat of arsenic in groundwater. Science 2020; 368:845.</a></li><li class="breakAll">US Environmental Protection Agency. Arsenic in Drinking Water. Available at: http://water.epa.gov/lawsregs/rulesregs/sdwa/arsenic/index.cfm (Accessed on May 30, 2020).</li><li><a class="nounderline abstract_t">Smith AH, Lingas EO, Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull World Health Organ 2000; 78:1093.</a></li><li><a class="nounderline abstract_t">Chakraborti D, Mukherjee SC, Pati S, et al. Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? Environ Health Perspect 2003; 111:1194.</a></li><li><a class="nounderline abstract_t">Chowdhury UK, Biswas BK, Chowdhury TR, et al. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect 2000; 108:393.</a></li><li><a class="nounderline abstract_t">Argos M, Kalra T, Rathouz PJ, et al. Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 2010; 376:252.</a></li><li><a class="nounderline abstract_t">Ahmad SA, Khan MH, Haque M. Arsenic contamination in groundwater in Bangladesh: implications and challenges for healthcare policy. Risk Manag Healthc Policy 2018; 11:251.</a></li><li><a class="nounderline abstract_t">Parvez F, Wasserman GA, Factor-Litvak P, et al. Arsenic exposure and motor function among children in Bangladesh. Environ Health Perspect 2011; 119:1665.</a></li><li><a class="nounderline abstract_t">Franzblau A, Lilis R. Acute arsenic intoxication from environmental arsenic exposure. Arch Environ Health 1989; 44:385.</a></li><li><a class="nounderline abstract_t">Lindenmayer G, Hoggett K, Burrow J, et al. A Sickening Tale. N Engl J Med 2018; 379:75.</a></li><li><a class="nounderline abstract_t">Mead MN. Arsenic: in search of an antidote to a global poison. Environ Health Perspect 2005; 113:A378.</a></li><li><a class="nounderline abstract_t">Mayer JE, Goldman RH. Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water. Int J Dermatol 2016; 55:e585.</a></li><li class="breakAll">World Health Organization. Arsenic in Drinking Water. Available at: www.who.int/water_sanitation_health/dwq/arsenic/en (Accessed on May 01, 2016).</li><li class="breakAll">World Health Organization. Arsenic. Available at: https://www.who.int/news-room/fact-sheets/detail/arsenic (Accessed on January 11, 2023).</li><li class="breakAll">US Food and Drug Administration. Supporting document for action level for arsenic in apple juice. 2013. Available at: https://www.fda.gov/food/chemical-metals-natural-toxins-pesticides-guidance-documents-regulations/supporting-document-action-level-arsenic-apple-juice (Accessed on February 07, 2022).</li><li class="breakAll">National Research Council. Arsenic in Drinking Water: 2001 Update. National Academy Press, Washington, DC 2001. Available at: www.nap.edu/catalog/10194/arsenic-in-drinking-water-2001-update (Accessed on May 30, 2020).</li><li class="breakAll">US Food and Drug Administration. Arsenic in food and dietary supplements. Available at: https://www.fda.gov/food/metals-and-your-food/arsenic-food-and-dietary-supplements (Accessed on February 07, 2022).</li><li><a class="nounderline abstract_t">Cubadda F, Jackson BP, Cottingham KL, et al. Human exposure to dietary inorganic arsenic and other arsenic species: State of knowledge, gaps and uncertainties. Sci Total Environ 2017; 579:1228.</a></li><li><a class="nounderline abstract_t">Jackson BP, Taylor VF, Karagas MR, et al. Arsenic, organic foods, and brown rice syrup. Environ Health Perspect 2012; 120:623.</a></li><li class="breakAll">Consumer Reports. Arsenic in your food. Available at: www.consumerreports.org/cro/magazine/2012/11/arsenic-in-your-food/index.htm (Accessed on January 30, 2022).</li><li class="breakAll">US Food and Drug Administration. For consumers: Seven things pregnant women and parents need to know about arsenic in rice and rice cereal. 2016. Available at: https://www.fda.gov/consumers/consumer-updates/consumers-seven-things-pregnant-women-and-parents-need-know-about-arsenic-rice-and-rice-cereal (Accessed on May 30, 2020).</li><li class="breakAll">Hirsch J. Arsenic and lead are in your fruit juice: What you need to know. 2019. Available at: https://www.consumerreports.org/food-safety/arsenic-and-lead-are-in-your-fruit-juice-what-you-need-to-know/ (Accessed on February 07, 2022).</li><li class="breakAll">US Food and Drug Administration. Arsenic in Apple Juice Analytical Results, 2005-2011 Toxic Elements Food and Foodware Program. Available at: www.fda.gov/food/foodborneillnesscontaminants/metals/ucm273328.htm (Accessed on February 07, 2022).</li><li class="breakAll">US Food and Drug Administration. Draft Guidance for Industry: Arsenic in Apple Juice - Action Level. https://www.fda.gov/Food/ResourcesForYou/Consumers/ucm271595.htm (Accessed on January 11, 2023).</li><li><a class="nounderline abstract_t">Gilbert-Diamond D, Cottingham KL, Gruber JF, et al. Rice consumption contributes to arsenic exposure in US women. Proc Natl Acad Sci U S A 2011; 108:20656.</a></li><li><a class="nounderline abstract_t">Karagas MR, Punshon T, Sayarath V, et al. Association of Rice and Rice-Product Consumption With Arsenic Exposure Early in Life. JAMA Pediatr 2016; 170:609.</a></li><li class="breakAll">American Academy of Pediatrics. Tips to reduce arsenic in your baby's diet. 2016. Available at: https://healthychildren.org/English/ages-stages/baby/feeding-nutrition/Pages/reduce-arsenic.aspx (Accessed on February 07, 2022).</li><li class="breakAll">US Food and Drug Administration. FDA proposes limit for inorganic arsenic in infant rice cereal. Available at: www.fda.gov/newsevents/newsroom/pressannouncements/ucm493740.htm (Accessed on February 07, 2022).</li><li><a class="nounderline abstract_t">Lasky T, Sun W, Kadry A, Hoffman MK. Mean total arsenic concentrations in chicken 1989-2000 and estimated exposures for consumers of chicken. Environ Health Perspect 2004; 112:18.</a></li><li class="breakAll">US Food and Drug Administration. Questions and answers on arsenic-based animal drugs. 2019. Available at: https://www.fda.gov/animal-veterinary/product-safety-information/questions-and-answers-arsenic-based-animal-drugs (Accessed on January 30, 2022).</li><li><a class="nounderline abstract_t">Nachman KE, Baron PA, Raber G, et al. Roxarsone, inorganic arsenic, and other arsenic species in chicken: a U.S.-based market basket sample. Environ Health Perspect 2013; 121:818.</a></li><li><a class="nounderline abstract_t">Saper RB, Kales SN, Paquin J, et al. Heavy metal content of ayurvedic herbal medicine products. JAMA 2004; 292:2868.</a></li><li><a class="nounderline abstract_t">Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 2008; 300:915.</a></li><li><a class="nounderline abstract_t">Gerhardt RE, Crecelius EA, Hudson JB. Moonshine-related arsenic poisoning. Arch Intern Med 1980; 140:211.</a></li><li><a class="nounderline abstract_t">Rose M, Lewis J, Langford N, et al. Arsenic in seaweed--forms, concentration and dietary exposure. Food Chem Toxicol 2007; 45:1263.</a></li><li><a class="nounderline abstract_t">Almela C, Clemente MJ, Vélez D, Montoro R. Total arsenic, inorganic arsenic, lead and cadmium contents in edible seaweed sold in Spain. Food Chem Toxicol 2006; 44:1901.</a></li><li class="breakAll">US Department of Labor. Occupational Safety and Health Administration. Available at: www.osha.gov/SLTC/arsenic/index.html (Accessed on February 08, 2022).</li><li class="breakAll">National Institute of Occupational Safety and Health. NIOSH Pocket Guide to Chemical Hazards. Available at: www.cdc.gov/niosh/npg/npgd0038.html (Accessed on February 08, 2022).</li><li class="breakAll">Environmental Protection Agency. Arsenical pesticides. In: Recognition and Management of Pesticide Poisonings, 6th ed, Washington, DC 2013. p.277. Available at: https://www.epa.gov/sites/production/files/documents/rmpp_6thed_ch15_arsenicals.pdf (Accessed on January 30, 2022).</li><li><a class="nounderline abstract_t">Eisler R. Arsenic hazards to humans, plants, and animals from gold mining. Rev Environ Contam Toxicol 2004; 180:133.</a></li><li class="breakAll">Environmental Protection Agency. Chromated arsenicals (CCA). Available at: https://www.epa.gov/ingredients-used-pesticide-products/chromated-arsenicals-cca (Accessed on February 07, 2022).</li><li><a class="nounderline abstract_t">Peters HA, Croft WA, Woolson EA, et al. Seasonal arsenic exposure from burning chromium-copper-arsenate-treated wood. JAMA 1984; 251:2393.</a></li><li><a class="nounderline abstract_t">Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62:3893.</a></li><li><a class="nounderline abstract_t">Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339:1341.</a></li><li class="breakAll">National Cancer Institute. Arsenic trioxide. 2019. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/arsenictrioxide (Accessed on January 30, 2022).</li><li><a class="nounderline abstract_t">Chiu C, Fisk CA, Rice BT, Garcia ECM. Arsenic Toxicity From the Ingestion of Terracotta Pottery. J Emerg Med 2022; 63:363.</a></li><li><a class="nounderline abstract_t">Chen Y, Graziano JH, Parvez F, et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. BMJ 2011; 342:d2431.</a></li><li class="breakAll">International Agency for Research on Cancer. Arsenic, Metals, Fibres, and Dusts: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 2012. Vol 100C.</li><li><a class="nounderline abstract_t">Smith AH, Marshall G, Roh T, et al. Lung, Bladder, and Kidney Cancer Mortality 40 Years After Arsenic Exposure Reduction. J Natl Cancer Inst 2018; 110:241.</a></li><li><a class="nounderline abstract_t">Bulka CM, Jones RM, Turyk ME, et al. Arsenic in drinking water and prostate cancer in Illinois counties: An ecologic study. Environ Res 2016; 148:450.</a></li><li><a class="nounderline abstract_t">Roh T, Steinmaus C, Marshall G, et al. Age at Exposure to Arsenic in Water and Mortality 30-40 Years After Exposure Cessation. Am J Epidemiol 2018; 187:2297.</a></li><li class="breakAll">National Toxicology Program. Arsenic and inorganic arsenic compounds. In: Report on carcinogens, 14th ed, US Department of Health and Human Services. 2016. Available at: https://ntp.niehs.nih.gov/ntp/roc/content/profiles/arsenic.pdf (Accessed on May 30, 2020).</li><li><a class="nounderline abstract_t">Steinmaus C, Ferreccio C, Yuan Y, et al. Elevated lung cancer in younger adults and low concentrations of arsenic in water. Am J Epidemiol 2014; 180:1082.</a></li><li><a class="nounderline abstract_t">Ferreccio C, González C, Milosavjlevic V, et al. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000; 11:673.</a></li><li><a class="nounderline abstract_t">Chiu HF, Ho SC, Yang CY. Lung cancer mortality reduction after installation of tap-water supply system in an arseniasis-endemic area in Southwestern Taiwan. Lung Cancer 2004; 46:265.</a></li><li><a class="nounderline abstract_t">Chen CL, Hsu LI, Chiou HY, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 2004; 292:2984.</a></li><li><a class="nounderline abstract_t">Chiou HY, Chiou ST, Hsu YH, et al. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001; 153:411.</a></li><li><a class="nounderline abstract_t">Ahsan H, Chen Y, Parvez F, et al. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study. Am J Epidemiol 2006; 163:1138.</a></li><li><a class="nounderline abstract_t">Rajiv SV, George M, Nandakumar G. Dermatological manifestations of arsenic exposure. J Skin Sex Transm Dis 2022.</a></li><li><a class="nounderline abstract_t">Ferreccio C, Smith AH, Durán V, et al. Case-control study of arsenic in drinking water and kidney cancer in uniquely exposed Northern Chile. Am J Epidemiol 2013; 178:813.</a></li><li><a class="nounderline abstract_t">Guo HR. The lack of a specific association between arsenic in drinking water and hepatocellular carcinoma. J Hepatol 2003; 39:383.</a></li><li><a class="nounderline abstract_t">Yang Y, McDonald AC, Wang X, et al. Arsenic exposures and prostate cancer risk: A multilevel meta-analysis. J Trace Elem Med Biol 2022; 72:126992.</a></li><li class="breakAll">National Research Council. Arsenic in Drinking Water. National Academy Press; Wasthington, DC 1999.</li><li><a class="nounderline abstract_t">Argos M, Kalra T, Pierce BL, et al. A prospective study of arsenic exposure from drinking water and incidence of skin lesions in Bangladesh. Am J Epidemiol 2011; 174:185.</a></li><li><a class="nounderline abstract_t">Yu HS, Lee CH, Chen GS. Peripheral vascular diseases resulting from chronic arsenical poisoning. J Dermatol 2002; 29:123.</a></li><li><a class="nounderline abstract_t">Tseng WP. Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 1977; 19:109.</a></li><li><a class="nounderline abstract_t">Lin TH, Huang YL. Chemical speciation of arsenic in urine of patients with blackfoot disease. Biol Trace Elem Res 1995; 48:251.</a></li><li class="breakAll">Feldman RG. Arsenic. In: Occupational and Environmental Neurotoxicology, Feldman RG (Ed), Lippincott-Raven, Philadelphia 1999.</li><li class="breakAll">Chhuttani P, Chopra J. Arsenic Poisoning. In: Handbook of Clinical Neurology: Intoxication of the Nervous System, part I, Vinken P, Bruyn G (Eds), North Holland, Amsterdam 1979. Vol 36, p.199.</li><li><a class="nounderline abstract_t">Feldman RG, Niles CA, Kelly-Hayes M, et al. Peripheral neuropathy in arsenic smelter workers. Neurology 1979; 29:939.</a></li><li><a class="nounderline abstract_t">Lagerkvist BJ, Zetterlund B. Assessment of exposure to arsenic among smelter workers: a five-year follow-up. Am J Ind Med 1994; 25:477.</a></li><li class="breakAll">Bleecker M. Toxic Peripheral Neuropathy. In: Environmental and Occupational Medicine, 4th ed., Rom W, Markowitz S (Eds), Lippincott Williams &amp; Wilkins, 2007. p.643.</li><li><a class="nounderline abstract_t">Mochizuki H. Arsenic Neurotoxicity in Humans. Int J Mol Sci 2019; 20.</a></li><li><a class="nounderline abstract_t">Supapong S, Phanthumchinda K, Srirattanaban J. Nerve conduction studies in chronic arsenic poisoning patients. J Med Assoc Thai 2004; 87 Suppl 2:S207.</a></li><li><a class="nounderline abstract_t">Morton WE, Caron GA. Encephalopathy: an uncommon manifestation of workplace arsenic poisoning? Am J Ind Med 1989; 15:1.</a></li><li><a class="nounderline abstract_t">Freeman JW, Couch JR. Prolonged encephalopathy with arsenic poisoning. Neurology 1978; 28:853.</a></li><li><a class="nounderline abstract_t">Beckett WS, Moore JL, Keogh JP, Bleecker ML. Acute encephalopathy due to occupational exposure to arsenic. Br J Ind Med 1986; 43:66.</a></li><li><a class="nounderline abstract_t">Rodríguez VM, Jiménez-Capdeville ME, Giordano M. The effects of arsenic exposure on the nervous system. Toxicol Lett 2003; 145:1.</a></li><li><a class="nounderline abstract_t">Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 2000; 133:881.</a></li><li><a class="nounderline abstract_t">Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol 2003; 21:3609.</a></li><li><a class="nounderline abstract_t">Wang CH, Chen CL, Hsiao CK, et al. Increased risk of QT prolongation associated with atherosclerotic diseases in arseniasis-endemic area in southwestern coast of Taiwan. Toxicol Appl Pharmacol 2009; 239:320.</a></li><li><a class="nounderline abstract_t">Rahman M. Arsenic and hypertension in Bangladesh. Bull World Health Organ 2002; 80:173.</a></li><li><a class="nounderline abstract_t">Chen CJ, Hsueh YM, Lai MS, et al. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995; 25:53.</a></li><li><a class="nounderline abstract_t">Rahman M, Tondel M, Ahmad SA, et al. Hypertension and arsenic exposure in Bangladesh. Hypertension 1999; 33:74.</a></li><li><a class="nounderline abstract_t">Jiang J, Liu M, Parvez F, et al. Association between Arsenic Exposure from Drinking Water and Longitudinal Change in Blood Pressure among HEALS Cohort Participants. Environ Health Perspect 2015; 123:806.</a></li><li><a class="nounderline abstract_t">Moon KA, Guallar E, Umans JG, et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. Ann Intern Med 2013; 159:649.</a></li><li><a class="nounderline abstract_t">James KA, Byers T, Hokanson JE, et al. Association between lifetime exposure to inorganic arsenic in drinking water and coronary heart disease in Colorado residents. Environ Health Perspect 2015; 123:128.</a></li><li><a class="nounderline abstract_t">Navas-Acien A, Sharrett AR, Silbergeld EK, et al. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am J Epidemiol 2005; 162:1037.</a></li><li><a class="nounderline abstract_t">Hernández-Zavala A, Del Razo LM, Aguilar C, et al. Alteration in bilirubin excretion in individuals chronically exposed to arsenic in Mexico. Toxicol Lett 1998; 99:79.</a></li><li><a class="nounderline abstract_t">Santra A, Das Gupta J, De BK, et al. Hepatic manifestations in chronic arsenic toxicity. Indian J Gastroenterol 1999; 18:152.</a></li><li><a class="nounderline abstract_t">Tseng CH, Tai TY, Chong CK, et al. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 2000; 108:847.</a></li><li><a class="nounderline abstract_t">Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Arsenic exposure and prevalence of type 2 diabetes in US adults. JAMA 2008; 300:814.</a></li><li><a class="nounderline abstract_t">Rahman M, Tondel M, Ahmad SA, Axelson O. Diabetes mellitus associated with arsenic exposure in Bangladesh. Am J Epidemiol 1998; 148:198.</a></li><li><a class="nounderline abstract_t">Chen Y, Ahsan H, Slavkovich V, et al. No association between arsenic exposure from drinking water and diabetes mellitus: a cross-sectional study in Bangladesh. Environ Health Perspect 2010; 118:1299.</a></li><li><a class="nounderline abstract_t">von Ehrenstein OS, Mazumder DN, Yuan Y, et al. Decrements in lung function related to arsenic in drinking water in West Bengal, India. Am J Epidemiol 2005; 162:533.</a></li><li><a class="nounderline abstract_t">Parvez F, Chen Y, Brandt-Rauf PW, et al. A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). Thorax 2010; 65:528.</a></li><li><a class="nounderline abstract_t">Westhoff DD, Samaha RJ, Barnes A Jr. Arsenic intoxication as a cause of megaloblastic anemia. Blood 1975; 45:241.</a></li><li><a class="nounderline abstract_t">Eichner ER. Erythroid karyorrhexis in the peripheral blood smear in severe arsenic poisoning: a comparison with lead poisoning. Am J Clin Pathol 1984; 81:533.</a></li><li><a class="nounderline abstract_t">Pralle H, Manz F. Influence of chronic arsenic poisoning on bone marrow morphology. A case report. Blut 1985; 50:51.</a></li><li><a class="nounderline abstract_t">Kales SN, Huyck KL, Goldman RH. Elevated urine arsenic: un-speciated results lead to unnecessary concern and further evaluations. J Anal Toxicol 2006; 30:80.</a></li><li class="breakAll">Centers for Disease Control and Prevention. National report on human exposure to environmental chemicals. Updated tables, March 2022. Available at: https://www.cdc.gov/exposurereport/index.html (Accessed on August 28, 2023).</li><li class="breakAll">National Health and Nutrition Examination SurveySpeciated Arsenics - Urine - Special Sample (UASS_I) https://wwwn.cdc.gov/Nchs/Nhanes/2015-2016/UASS_I.htm (Accessed on December 02, 2021).</li><li class="breakAll">WorkSafe. Biological Exposure Index (BEI) review: Arsenic and soluble compounds AS As (arsenic CAS no: 7440-38-2). New Zealand Government 2020. Available at: https://worksafe.govt.nz/dmsdocument/26972-biological-exposure-index-bei-review-arsenic/latest (Accessed on February 09, 2022).</li><li><a class="nounderline abstract_t">Steindel SJ, Howanitz PJ. The uncertainty of hair analysis for trace metals. JAMA 2001; 285:83.</a></li><li><a class="nounderline abstract_t">Seidel S, Kreutzer R, Smith D, et al. Assessment of commercial laboratories performing hair mineral analysis. JAMA 2001; 285:67.</a></li><li><a class="nounderline abstract_t">Kosnett MJ. The role of chelation in the treatment of arsenic and mercury poisoning. J Med Toxicol 2013; 9:347.</a></li><li><a class="nounderline abstract_t">Guha Mazumder DN, De BK, Santra A, et al. Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water. J Toxicol Clin Toxicol 2001; 39:665.</a></li><li><a class="nounderline abstract_t">Guha Mazumder DN, Ghoshal UC, Saha J, et al. Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water. J Toxicol Clin Toxicol 1998; 36:683.</a></li><li><a class="nounderline abstract_t">Landrigan PJ, Goldman LR. Children's vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy. Health Aff (Millwood) 2011; 30:842.</a></li><li class="breakAll">American Academy of Pediatrics Council on Environmental Health. Children's unique vulnerabilities to environmental hazards. In: Pediatric Environmental Health, 4th ed, Etzel RA, Balk SJ (Eds), American Academy of Pediatrics, 2019. p.17.</li><li class="breakAll">FDA finalizes AAP-supported limit on inorganic arsenic in rice cereals. AAP News. https://publications.aap.org/aapnews/news/9138/ (Accessed on October 13, 2022).</li><li><a class="nounderline abstract_t">Korioth T. Parent Plus: Limit infants’ exposure to arsenic by feeding a variety of grains. AAP News 2016.</a></li><li class="breakAll">AAP: Babies should eat a varied diet to protect against heavy metals in commercial, homemade food. AAP News. https://publications.aap.org/aapnews/news/21916/AAP-Babies-should-eat-a-varied-diet-to-protect (Accessed on September 11, 2023).</li><li class="breakAll">Pediatric Environmental Health Specialty Units: Information on Arsenic in Food: Guidance for Parents and Families, October 2012. Available at: www.pehsu.net/Public_Arsenic_in_Food.html (Accessed on May 01, 2016).</li><li><a class="nounderline abstract_t">Ahmad SA, Sayed MH, Barua S, et al. Arsenic in drinking water and pregnancy outcomes. Environ Health Perspect 2001; 109:629.</a></li><li><a class="nounderline abstract_t">Hopenhayn-Rich C, Browning SR, Hertz-Picciotto I, et al. Chronic arsenic exposure and risk of infant mortality in two areas of Chile. Environ Health Perspect 2000; 108:667.</a></li><li><a class="nounderline abstract_t">Laine JE, Bailey KA, Rubio-Andrade M, et al. Maternal arsenic exposure, arsenic methylation efficiency, and birth outcomes in the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort in Mexico. Environ Health Perspect 2015; 123:186.</a></li><li><a class="nounderline abstract_t">Quansah R, Armah FA, Essumang DK, et al. Association of arsenic with adverse pregnancy outcomes/infant mortality: a systematic review and meta-analysis. Environ Health Perspect 2015; 123:412.</a></li><li><a class="nounderline abstract_t">Concha G, Vogler G, Nermell B, Vahter M. Low-level arsenic excretion in breast milk of native Andean women exposed to high levels of arsenic in the drinking water. Int Arch Occup Environ Health 1998; 71:42.</a></li><li><a class="nounderline abstract_t">Sternowsky HJ, Moser B, Szadkowsky D. Arsenic in breast milk during the first 3 months of lactation. Int J Hyg Environ Health 2002; 205:405.</a></li><li><a class="nounderline abstract_t">Tillett T. Is arsenic "lactation intolerant"? Environ Health Perspect 2008; 116:A306.</a></li><li><a class="nounderline abstract_t">Carignan CC, Cottingham KL, Jackson BP, et al. Estimated exposure to arsenic in breastfed and formula-fed infants in a United States cohort. Environ Health Perspect 2015; 123:500.</a></li></ol></div><div id="topicVersionRevision">Topic 2778 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mundy SW. Arsenic. In: Goldfrank's Toxicologic Emergencies, 11th ed, Nelson L, Hoffman R, Howland MA, et al (Eds), McGraw-Hill Education, 2019. p.1237.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://apps.who.int/iris/bitstream/handle/10665/329482/WHO-CED-PHE-EPE-19.4.1-eng.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : World Health Organization. Exposure to arsenic: A major public concern. 2019. Available at: https://apps.who.int/iris/bitstream/handle/10665/329482/WHO-CED-PHE-EPE-19.4.1-eng.pdf (Accessed on January 25, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30358658" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Arsenic Exposure, Assessment, Toxicity, Diagnosis, and Management: Guidance for Occupational and Environmental Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31906333" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28024743" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human exposure to organic arsenic species from seafood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28024743" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Human exposure to organic arsenic species from seafood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28024743" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human exposure to organic arsenic species from seafood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Biochemical toxicology of arsenic</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Biochemical toxicology of arsenic</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20183531" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Biomonitoring for environmental exposures to arsenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20183531" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Biomonitoring for environmental exposures to arsenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26115410" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mechanisms Underlying Latent Disease Risk Associated with Early-Life Arsenic Exposure: Current Research Trends and Scientific Gaps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19787300" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Arsenic exposure and cardiovascular disorders: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19787300" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Arsenic exposure and cardiovascular disorders: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19787300" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Arsenic exposure and cardiovascular disorders: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458756" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458756" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458756" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33709865" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Arsenic exposure from groundwater: environmental contamination, human health effects, and sustainable solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32439786" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Global threat of arsenic in groundwater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32439786" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Global threat of arsenic in groundwater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11019458" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Contamination of drinking-water by arsenic in Bangladesh: a public health emergency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842773" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811564" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Groundwater arsenic contamination in Bangladesh and West Bengal, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20646756" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30584381" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Arsenic contamination in groundwater in Bangladesh: implications and challenges for healthcare policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742576" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Arsenic exposure and motor function among children in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2610527" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute arsenic intoxication from environmental arsenic exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29972758" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A Sickening Tale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15929879" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Arsenic: in search of an antidote to a global poison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420023" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420023" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420023" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420023" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420023" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420023" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Arsenic and skin cancer in the USA: the current evidence regarding arsenic-contaminated drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27914647" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Human exposure to dietary inorganic arsenic and other arsenic species: State of knowledge, gaps and uncertainties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336149" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Arsenic, organic foods, and brown rice syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336149" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Arsenic, organic foods, and brown rice syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336149" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Arsenic, organic foods, and brown rice syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336149" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Arsenic, organic foods, and brown rice syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336149" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Arsenic, organic foods, and brown rice syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336149" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Arsenic, organic foods, and brown rice syrup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22143778" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rice consumption contributes to arsenic exposure in US women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111102" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Association of Rice and Rice-Product Consumption With Arsenic Exposure Early in Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111102" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Association of Rice and Rice-Product Consumption With Arsenic Exposure Early in Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111102" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of Rice and Rice-Product Consumption With Arsenic Exposure Early in Life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14698925" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mean total arsenic concentrations in chicken 1989-2000 and estimated exposures for consumers of chicken.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14698925" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mean total arsenic concentrations in chicken 1989-2000 and estimated exposures for consumers of chicken.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23694900" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Roxarsone, inorganic arsenic, and other arsenic species in chicken: a U.S.-based market basket sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598918" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Heavy metal content of ayurvedic herbal medicine products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18728265" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7352816" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Moonshine-related arsenic poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336439" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Arsenic in seaweed--forms, concentration and dietary exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901603" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Total arsenic, inorganic arsenic, lead and cadmium contents in edible seaweed sold in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901603" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Total arsenic, inorganic arsenic, lead and cadmium contents in edible seaweed sold in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901603" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Total arsenic, inorganic arsenic, lead and cadmium contents in edible seaweed sold in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901603" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Total arsenic, inorganic arsenic, lead and cadmium contents in edible seaweed sold in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561078" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Arsenic hazards to humans, plants, and animals from gold mining.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561078" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Arsenic hazards to humans, plants, and animals from gold mining.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6708290" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Seasonal arsenic exposure from burning chromium-copper-arsenate-treated wood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124315" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mechanisms of action of arsenic trioxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801394" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9801394" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36229316" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Arsenic Toxicity From the Ingestion of Terracotta Pottery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546419" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546419" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29069505" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Lung, Bladder, and Kidney Cancer Mortality 40 Years After Arsenic Exposure Reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27136670" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Arsenic in drinking water and prostate cancer in Illinois counties: An ecologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30084889" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Age at Exposure to Arsenic in Water and Mortality 30-40 Years After Exposure Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30084889" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Age at Exposure to Arsenic in Water and Mortality 30-40 Years After Exposure Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371173" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Elevated lung cancer in younger adults and low concentrations of arsenic in water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11055628" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lung cancer and arsenic concentrations in drinking water in Chile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15541810" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Lung cancer mortality reduction after installation of tap-water supply system in an arseniasis-endemic area in Southwestern Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613666" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11226969" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16624965" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dermatological manifestations of arsenic exposure</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764934" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Case-control study of arsenic in drinking water and kidney cancer in uniquely exposed Northern Chile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12927924" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The lack of a specific association between arsenic in drinking water and hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35550984" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Arsenic exposures and prostate cancer risk: A multilevel meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35550984" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Arsenic exposures and prostate cancer risk: A multilevel meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576319" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A prospective study of arsenic exposure from drinking water and incidence of skin lesions in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990246" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Peripheral vascular diseases resulting from chronic arsenical poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/908285" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects and dose--response relationships of skin cancer and blackfoot disease with arsenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398945" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chemical speciation of arsenic in urine of patients with blackfoot disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398945" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Chemical speciation of arsenic in urine of patients with blackfoot disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398945" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Chemical speciation of arsenic in urine of patients with blackfoot disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/224345" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Peripheral neuropathy in arsenic smelter workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7516623" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Assessment of exposure to arsenic among smelter workers: a five-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7516623" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Assessment of exposure to arsenic among smelter workers: a five-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31336801" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Arsenic Neurotoxicity in Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083189" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Nerve conduction studies in chronic arsenic poisoning patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2929604" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Encephalopathy: an uncommon manifestation of workplace arsenic poisoning?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/567305" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prolonged encephalopathy with arsenic poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3947565" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Acute encephalopathy due to occupational exposure to arsenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12962969" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The effects of arsenic exposure on the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11103058" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512391" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of arsenic trioxide on QT interval in patients with advanced malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573547" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Increased risk of QT prolongation associated with atherosclerotic diseases in arseniasis-endemic area in southwestern coast of Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953799" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Arsenic and hypertension in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843753" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Increased prevalence of hypertension and long-term arsenic exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9931084" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hypertension and arsenic exposure in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25816368" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Association between Arsenic Exposure from Drinking Water and Longitudinal Change in Blood Pressure among HEALS Cohort Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24061511" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25350952" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Association between lifetime exposure to inorganic arsenic in drinking water and coronary heart disease in Colorado residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269585" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817078" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Alteration in bilirubin excretion in individuals chronically exposed to arsenic in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10531716" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Hepatic manifestations in chronic arsenic toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017889" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18714061" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Arsenic exposure and prevalence of type 2 diabetes in US adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9676702" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Diabetes mellitus associated with arsenic exposure in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813654" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : No association between arsenic exposure from drinking water and diabetes mellitus: a cross-sectional study in Bangladesh.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093295" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Decrements in lung function related to arsenic in drinking water in West Bengal, India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20522851" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1120185" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Arsenic intoxication as a cause of megaloblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6702757" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Erythroid karyorrhexis in the peripheral blood smear in severe arsenic poisoning: a comparison with lead poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3967100" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Influence of chronic arsenic poisoning on bone marrow morphology. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620536" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Elevated urine arsenic: un-speciated results lead to unnecessary concern and further evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620536" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Elevated urine arsenic: un-speciated results lead to unnecessary concern and further evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620536" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Elevated urine arsenic: un-speciated results lead to unnecessary concern and further evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620536" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Elevated urine arsenic: un-speciated results lead to unnecessary concern and further evaluations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150115" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The uncertainty of hair analysis for trace metals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11150111" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Assessment of commercial laboratories performing hair mineral analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178900" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The role of chelation in the treatment of arsenic and mercury poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11778664" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Randomized placebo-controlled trial of 2,3-dimercapto-1-propanesulfonate (DMPS) in therapy of chronic arsenicosis due to drinking arsenic-contaminated water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865236" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Randomized placebo-controlled trial of 2,3-dimercaptosuccinic acid in therapy of chronic arsenicosis due to drinking arsenic-contaminated subsoil water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543423" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Children's vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543423" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Children's vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543423" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Children's vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Parent Plus: Limit infants’exposure to arsenic by feeding a variety of grains</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Parent Plus: Limit infants’exposure to arsenic by feeding a variety of grains</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Parent Plus: Limit infants’exposure to arsenic by feeding a variety of grains</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445518" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Arsenic in drinking water and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903622" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Chronic arsenic exposure and risk of infant mortality in two areas of Chile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25325819" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Maternal arsenic exposure, arsenic methylation efficiency, and birth outcomes in the Biomarkers of Exposure to ARsenic (BEAR) pregnancy cohort in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25626053" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Association of arsenic with adverse pregnancy outcomes/infant mortality: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9523248" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Low-level arsenic excretion in breast milk of native Andean women exposed to high levels of arsenic in the drinking water.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12173541" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Arsenic in breast milk during the first 3 months of lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18629342" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Is arsenic "lactation intolerant"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707031" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Estimated exposure to arsenic in breastfed and formula-fed infants in a United States cohort.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
